[
  {
    "ts": null,
    "headline": "PRIMECAP Management's Strategic Moves: Significant Reduction in Eli Lilly and Co",
    "summary": "Insights from the Second Quarter 2025 13F Filing",
    "url": "https://finnhub.io/api/news?id=7fb1fd6b1c228da57ef03c6f233d65a5b312520980f9f4cd1db58c19da03abfe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754949703,
      "headline": "PRIMECAP Management's Strategic Moves: Significant Reduction in Eli Lilly and Co",
      "id": 136315979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insights from the Second Quarter 2025 13F Filing",
      "url": "https://finnhub.io/api/news?id=7fb1fd6b1c228da57ef03c6f233d65a5b312520980f9f4cd1db58c19da03abfe"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Popped Today",
    "summary": "Eli Lilly stock got cheaper last week. Investors now get a second bite at the delicious GLP-1 apple.",
    "url": "https://finnhub.io/api/news?id=359af9c8662093fd808eac223e8d7d694c1290c0e4b6dea09b3f867b9c6c4e7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754941697,
      "headline": "Why Eli Lilly Stock Popped Today",
      "id": 136315980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock got cheaper last week. Investors now get a second bite at the delicious GLP-1 apple.",
      "url": "https://finnhub.io/api/news?id=359af9c8662093fd808eac223e8d7d694c1290c0e4b6dea09b3f867b9c6c4e7d"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
    "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930844,
      "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
      "id": 136311902,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372801568/image_1372801568.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded following a decline the previous week. The stock had dropped sharply the previous week after the company released its Q2 2025 earnings report. Although the company beat earnings and revenue expectations and raised its full-year guidance, the positive news was overshadowed by disappointing trial data for its oral weight-loss drug, orforglipron. The drug's trial results showe",
    "url": "https://finnhub.io/api/news?id=344e9963bf11634938401c116ad19f33a73d4c0b447300c8534b089a4ce14526",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754929868,
      "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today",
      "id": 136310487,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded following a decline the previous week. The stock had dropped sharply the previous week after the company released its Q2 2025 earnings report. Although the company beat earnings and revenue expectations and raised its full-year guidance, the positive news was overshadowed by disappointing trial data for its oral weight-loss drug, orforglipron. The drug's trial results showe",
      "url": "https://finnhub.io/api/news?id=344e9963bf11634938401c116ad19f33a73d4c0b447300c8534b089a4ce14526"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d760190d58fc9720f109e3ae63649819cdcf0efabaf424113a6ec53619b4a731",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754929860,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 136330957,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d760190d58fc9720f109e3ae63649819cdcf0efabaf424113a6ec53619b4a731"
    }
  },
  {
    "ts": null,
    "headline": "Lilly first to opt for confidential reimbursement price in Germany",
    "summary": "This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.",
    "url": "https://finnhub.io/api/news?id=a4cb81de781f20930669c5bf3185e0d320e3b51f6f8011f4668f91687424d5ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754929544,
      "headline": "Lilly first to opt for confidential reimbursement price in Germany",
      "id": 136310488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.",
      "url": "https://finnhub.io/api/news?id=a4cb81de781f20930669c5bf3185e0d320e3b51f6f8011f4668f91687424d5ed"
    }
  },
  {
    "ts": null,
    "headline": "Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?",
    "summary": "LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.",
    "url": "https://finnhub.io/api/news?id=3d2032d35e68a70787dc04c47fff3ff26dce4b68551d86c5b28c7cebe2aa08e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754922180,
      "headline": "Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?",
      "id": 136310489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.",
      "url": "https://finnhub.io/api/news?id=3d2032d35e68a70787dc04c47fff3ff26dce4b68551d86c5b28c7cebe2aa08e5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) announced positive results from its Phase 3 ATTAIN-1 trial of Orforglipron, which is an oral drug for overweight adults without diabetes. The trial, which lasted 72 weeks and included 3,127 participants, showed [因",
    "url": "https://finnhub.io/api/news?id=f233f3dad8021f94f821120693f6250d679b17512b57f29d7f2ea19564204e2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754921974,
      "headline": "Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron",
      "id": 136310490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) announced positive results from its Phase 3 ATTAIN-1 trial of Orforglipron, which is an oral drug for overweight adults without diabetes. The trial, which lasted 72 weeks and included 3,127 participants, showed [因",
      "url": "https://finnhub.io/api/news?id=f233f3dad8021f94f821120693f6250d679b17512b57f29d7f2ea19564204e2a"
    }
  },
  {
    "ts": null,
    "headline": "Lilly (LLY) Reliance on International Sales: What Investors Need to Know",
    "summary": "Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=f30620aed488c583e531ffd0d1c051826ea59a583a47c79718ecc63446579593",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754918104,
      "headline": "Lilly (LLY) Reliance on International Sales: What Investors Need to Know",
      "id": 136310491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=f30620aed488c583e531ffd0d1c051826ea59a583a47c79718ecc63446579593"
    }
  },
  {
    "ts": null,
    "headline": "Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?",
    "summary": "Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.",
    "url": "https://finnhub.io/api/news?id=657e4b986a3644724c9843d0f2042d9ca363503b15e12a92fd0826893eccf0eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917920,
      "headline": "Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?",
      "id": 136310492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.",
      "url": "https://finnhub.io/api/news?id=657e4b986a3644724c9843d0f2042d9ca363503b15e12a92fd0826893eccf0eb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=3bb12c868e97822157536c4d399cf24d16be059409ddf6639891ba77c7535dd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917204,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136294231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=3bb12c868e97822157536c4d399cf24d16be059409ddf6639891ba77c7535dd5"
    }
  },
  {
    "ts": null,
    "headline": "Find Oversold Stocks to Buy at a Discount With This Barchart Screener",
    "summary": "Instead of chasing stocks that are running to new highs, here's a method for scooping up beaten-down stocks that are trading at oversold levels.",
    "url": "https://finnhub.io/api/news?id=d394e02ebffaf7d5eab27928a584c1b02c0445a9f82e6c9a98c6803e907de907",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754916376,
      "headline": "Find Oversold Stocks to Buy at a Discount With This Barchart Screener",
      "id": 136294232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Instead of chasing stocks that are running to new highs, here's a method for scooping up beaten-down stocks that are trading at oversold levels.",
      "url": "https://finnhub.io/api/news?id=d394e02ebffaf7d5eab27928a584c1b02c0445a9f82e6c9a98c6803e907de907"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes",
    "summary": "Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I rate NVO stock a Hold.",
    "url": "https://finnhub.io/api/news?id=2a0413a9feb8b5fc6572dc74d8956fad78f1973e30166363bbe98e0416edf08d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754913096,
      "headline": "Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes",
      "id": 136295676,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305425/image_2158305425.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I rate NVO stock a Hold.",
      "url": "https://finnhub.io/api/news?id=2a0413a9feb8b5fc6572dc74d8956fad78f1973e30166363bbe98e0416edf08d"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded Eli Lilly and Company (NYSE:LLY) to Market Perform from Outperform with a $715 price target. The rating update came after Eli Lilly and Company (NYSE:LLY) posted its fiscal Q2 2025 earnings the same day, [因",
    "url": "https://finnhub.io/api/news?id=8bf80143ef0d146780f617b421efccffc75529ae9e105e06440d1d2faed6dd14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754912771,
      "headline": "Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform",
      "id": 136294233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded Eli Lilly and Company (NYSE:LLY) to Market Perform from Outperform with a $715 price target. The rating update came after Eli Lilly and Company (NYSE:LLY) posted its fiscal Q2 2025 earnings the same day, [因",
      "url": "https://finnhub.io/api/news?id=8bf80143ef0d146780f617b421efccffc75529ae9e105e06440d1d2faed6dd14"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Enough Is Enough",
    "summary": "Novo Nordisk A/S's Q2 dip sparks contrarian buy potential. Click for my look at NVO earnings and why I think concern about recent company events is overblown.",
    "url": "https://finnhub.io/api/news?id=1bf16b4469ac2202392e254d17418b6b70fe544d515c7836dd48bdb2c219143e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754909333,
      "headline": "Novo Nordisk: Enough Is Enough",
      "id": 136294865,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1740765674/image_1740765674.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S's Q2 dip sparks contrarian buy potential. Click for my look at NVO earnings and why I think concern about recent company events is overblown.",
      "url": "https://finnhub.io/api/news?id=1bf16b4469ac2202392e254d17418b6b70fe544d515c7836dd48bdb2c219143e"
    }
  },
  {
    "ts": null,
    "headline": "Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities",
    "summary": "Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. Read more here",
    "url": "https://finnhub.io/api/news?id=256ea8bb2e23b7ca971a343047437044e07eec4a066f579cd2fa3dc2bb15f49b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754907483,
      "headline": "Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities",
      "id": 136294096,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. Read more here",
      "url": "https://finnhub.io/api/news?id=256ea8bb2e23b7ca971a343047437044e07eec4a066f579cd2fa3dc2bb15f49b"
    }
  },
  {
    "ts": null,
    "headline": "What To Do With These Seven Stocks After They Plunged",
    "summary": "Discover how S&P 500 growth is driven by mega-cap tech stocks while other sectors lag.",
    "url": "https://finnhub.io/api/news?id=e6bcbf04b4e3b464cb783a470e821a18ffac125785b8aff4200efd8e149c0e70",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754904054,
      "headline": "What To Do With These Seven Stocks After They Plunged",
      "id": 136293834,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214880916/image_2214880916.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover how S&P 500 growth is driven by mega-cap tech stocks while other sectors lag.",
      "url": "https://finnhub.io/api/news?id=e6bcbf04b4e3b464cb783a470e821a18ffac125785b8aff4200efd8e149c0e70"
    }
  }
]